The results of imatinib therapy for patients with primary eosinophilic disorders.
Helbig
Grzegorz
G
Stella-Holowiecka
Beata
B
Grosicki
Sebastian
S
Bober
Grazyna
G
Krawczyk
Magorzata
M
Wojnar
Jerzy
J
Reiter
Andreas
A
Hochhaus
Andreas
A
Holowiecki
Jerzy
J
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D014408:Biomarkers, Tumor / Q000032:analysis / Q000235:genetics; D004341:Drug Evaluation; D004802:Eosinophilia / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000188:drug therapy* / Q000235:genetics; D000068877:Imatinib Mesylate; D008297:Male; D008875:Middle Aged; D009196:Myeloproliferative Disorders / Q000188:drug therapy; D009363:Neoplasm Proteins / Q000032:analysis / Q000235:genetics; D015514:Oncogene Proteins, Fusion / Q000032:analysis / Q000235:genetics; D010879:Piperazines / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000032:analysis / Q000235:genetics; D016896:Treatment Outcome; D039221:mRNA Cleavage and Polyadenylation Factors / Q000032:analysis / Q000235:genetics
D000970:Antineoplastic Agents; D001549:Benzamides; D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins; D015514:Oncogene Proteins, Fusion; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D039221:mRNA Cleavage and Polyadenylation Factors; D000068877:Imatinib Mesylate; C479819:FIP1L1-PDGFRA fusion protein, human; D020796:Receptor, Platelet-Derived Growth Factor alpha